• Fluconazole packaged and labeled.

click on thumbnail to zoom
SKU: F010

  Click 'Bulk Order' for 10 or more
Price: make selection(s)

Fluconazole is broad-spectrum fungistatic triazole antifungal. Fluconazole targets  ergosterol synthesis in a wide range of fungal species such as Candida spp., Cryptococcus neoformans and dermatophytes.    It is insoluble in water (0.001 mg/ml).

    CAS Number


    Molecular Formula


    Molecular Weight


    Mechanism of Action

    Fluconazole interferes with the conversion of lanosterol to ergosterol, an essential cell membrane component. The inhibition of ergosterol synthesis increases cell permeability which disrupts normal cellular function.

    Resistance to antifungals can include alteration in drug target, alteration in sterol biosynthesis, reduction in the intercellular concentration of target enzyme, or overexpression of the antifungal drug target (Ghannoum and Rice, 1999).

    Storage Conditions


    Tariff Code



    Broad-spectrum including Candida spp., Cryptococcus neoformans and dermatophytes.


    Eukaryotic Cell Culture Applications

    There is no relationship between in vitro and in vivo activities for this compound, thus antifungal efficacy was mainly proved in animal models, and has low toxicity (Vincent-Ballereau et al, 1991).

    Microbiology Applications

    Fluconazole is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram- negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options.  Representative MIC values include:

      •  Blastomyces dermatidis 1 µg/ml – 64 µg/ml
      • Candida albicans ≤ 0.0313 µg/mL - 8 µg/mL
      • For a representative list of Fluconazole MIC values, click here.





    White or almost white crystalline powder



    Impurity Profile

    Impurity A: Not more than 0.2%
    Impurity B: Not more than 0.1%
    Impurity C: Not more than 0.2%
    Total unknown impurities: Not more than 0.3%
    Total impurities: Not more than 1.5%


    (On Dried Basis): 98.0-102.0%

    Loss on Drying


    Residue On Ignition

    Not more than 0.1%



    Ghannoum MA and Rice LB  (1999)  Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.  Clin.  Microbiol. Rev. 12 (4):501-517  PMID 10515900

     Re JH et al (1997)  Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida Infections. Clin. Infect. Dis. 24(2):235–247

    Sobel, JD and Akins RA (2004)  Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium.  Antimicrob. Agents Chemother. 48(1):161-167

    Vincent-Ballereau FN, Patey ON, Lafaix C (1991)  Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections.  Pharm Weekbl Sci. 13(2):45-57  1870943

Other Items In This Category